Advances in Therapy

Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives

By Margherita Grasso, Viviana Maggio, Filippo Caraci, Manfredi Rizzo

Figure 1 from Advances in Therapy — Figure 1. Grasso et al.

ReviewInterventions

The paper

Margherita Grasso, Viviana Maggio, Filippo Caraci, Manfredi Rizzo

I.R.C.C.S. Oasi Maria SS; Ras al-Khaimah Medical and Health Sciences University

Advances in Therapy, 22 Aug 2026

doi.org/10.1007/s12325-026-03760-8 PubMed 42631802

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Frontiers in Aging Neuroscience4 Oct 2026
COVID-19 tied to higher dementia risk in older adults with diabetes
Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk